Xeljanz (Tofacitinib) Approved for Ulcerative Colitis
WEDNESDAY, May 30, 2018 -- U.S. Food and Drug Administration approval of Xeljanz (tofacitinib) has been expanded to include adults with active moderate-to-severe ulcerative colitis, the agency said Wednesday.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease, characterized by recurring flares of abdominal pain and bloody diarrhea. Symptoms also may include fatigue, weight loss and fever.
Some 900,000 people in the United States have UC, for which there is no cure, the FDA said in a news release.
Xeljanz was first approved in 2012 for rheumatoid arthritis, and in 2017 for psoriatic arthritis.
In clinical studies evaluating the pill's use for UC, the most common side effects were diarrhea, high cholesterol, headache, herpes zoster (shingles) infection, cold-like symptoms, rash and upper respiratory infection.
The drug's label includes the agency's most serious "boxed warning" of less common adverse reactions including serious infections and cancer, the FDA said.
The agency warned against using Xeljanz in tandem with biological therapies for UC, or with potent medications that suppress the body's immune system.
Xeljanz is produced by New York City-based Pfizer.
© 2020 HealthDay. All rights reserved.
Posted: May 2018
Read this next
FRIDAY, July 10, 2020 -- A low-fat, high-fiber diet may improve the quality of life of patients with ulcerative colitis, a new study finds. "Patients with inflammatory bowel...
TUESDAY, June 9, 2020 -- There isn't enough scientific evidence to support using probiotics to treat most digestive disorders, according to a new American Gastroenterological...
MONDAY, March 23, 2020 -- People taking steroids to treat chronic inflammatory diseases are at high risk for developing high blood pressure, British investigators...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.